<DOC>
	<DOCNO>NCT02119052</DOCNO>
	<brief_summary>Autosomal dominant polycystic kidney disease ( ADPKD ) associate development variety extrarenal manifestation polycystic liver disease common . The investigator aim assess change time liver volume ADPKD patient whether affected treatment somatostatin analogue , octreotide . 35 ADPKD patient ( 14 male ) age 34Â±8 year randomly assign 36 month treatment placebo ( n=18 ) octreotide ( n=17 ) . Clinical liver parameter magnetic resonance ( RM ) evaluate baseline , study end 24 month drug withdrawal .</brief_summary>
	<brief_title>Effects Somatostatin Liver ADPKD</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>diagnosis autosomal dominant polycystic kidney liver disease glomerular filtration rate great 40 ml/min diabetes mellitus proteinuria great 1 g/24 hour significant glomerular disease urinary tract lithiasis infection symptomatic gallstone biliary sludge cancer pregnant woman lactanting woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>